OPT Congress 2026 is the leading industry event for scientists, directors, and technology providers driving innovation across oligonucleotide, mRNA, and peptide therapeutics. Now in its 11th year, the event features expanded programming including a new Peptides & Emerging Drug Conjugates conference, with a focus on AI-enabled design, extrahepatic delivery, s…
CureDuchenne, the leading Duchenne patient advocacy organization, will discuss its initiatives to accelerate the development and regulatory approval of the first drugs to treat Duc…
Chemical modification is the key to the success of making drugs out of oligonucleotides. Breakthroughs in LNPs formulation and trivalent GalNAc conjugation of chemically modified o…
Successes in oligonucleotide therapeutics have spurred the creation of bespoke therapies for rare genetic conditions, even for single patients. This talk will review lessons, chall…
Much is known about biochemical properties of ADAR RNA editing enzymes from decades of in vitro studies, but how these properties correlate with in vivo editing is not always clear…
An audience of 34 companies, parsed from the program.
The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.
50% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.
Of 4 on the bill · classified by free-text title